VRTXVertex Pharmaceuticals Incorporated

$125B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$870M+33.5% YoY

Gross Profit

$748M85.9% margin

Operating Income

$128M14.7% margin

Net Income

$1.6B178.2% margin

EPS (Diluted)

$5.97

QoQ Revenue Growth

+10.9%

Cash Flow

Operating Cash Flow

$315M

Free Cash Flow

$299M

Stock-Based Comp.

$79M

Balance Sheet

Total Assets

$6.2B

Total Liabilities

$1.8B

Stockholders' Equity

$4.4B

Cash & Equivalents

$2.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$870M	$652M	+33.5%
Gross Profit	$748M	$568M	+31.8%
Operating Income	$128M	$126M	+1.6%
Net Income	$1.6B	$101M	+1440.0%

Revenue Segments

ORKAMBI

$315M36%

SYMDEKO/SYMKEVI

$294M34%

KALYDECO

$259M30%

Geographic Segments

UNITED STATES

$677M59%

Non-US

$332M29%

Europe

$142M12%

VRTX Q4 2018 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena